Form 10-Q PLIANT THERAPEUTICS, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital
May 7, 2024 6:19 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $45.00 (from $54.00) while maintaining a Outperform rating.
The analyst comments "PLRX's IPF program remains on track with the ph.IIb expected to complete enrollment 1Q25. While this likely... More
Pliant Therapeutics (PLRX) PT Lowered to $44 at Citi
May 7, 2024 5:46 AM EDTCiti analyst David Lebowitz lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $44.00 (from $45.00) while maintaining a Buy rating.
The analyst comments "Pliant reported 1Q24 financial results and provided an update on the status of its pipeline programs. Over the... More
